SAB Biotherapeutics, Inc. (SABS) stock forecast and price target
Price $2.96 · data as of November 13, 2026
12-month price target
Average target$11.64
Upside / downside+293.1%
Analysts11
ConsensusStrong buy
Low $6.00Average $11.64High $16.00
Gold marker: average target · white marker: today’s price ($2.96)
Analyst ratings
Strong buy 1Buy 10Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.13 | −39.5% | $0 |
| Next fiscal year ends December 31, 2027 | $-0.94 | +16.3% | $62500 |
| Next quarter ends December 31, 2026 | $-0.24 | +40.6% | $0 |
| Quarter after ends March 31, 2027 | $-0.25 | — | $0 |
Consensus of the analysts covering SAB Biotherapeutics, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the SAB Biotherapeutics stock price target?
The average 12-month target from 11 analysts is $11.64, 293.1% above the current price of $2.96 Targets range from $6.00 to $16.00.
Is SAB Biotherapeutics a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 10 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is SAB Biotherapeutics expected to earn?
Analysts expect EPS of $-1.13 for the fiscal year ending December 31, 2026 and $-0.94 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.